GlobeNewswire

Roche launches new ways to use their cardiovascular tests empowering clinicians to improve diagnosis and treatment of millions of people

Share
  • Cardiovascular diseases are responsible for 17.9 million deaths every year¹, a third of all deaths globally²
  • Roche announces five new intended uses for key cardiac biomarkers to help identify cardiovascular risk, better diagnose patients and support early treatment
  • Early diagnosis and treatment can contribute to saving or improving people's lives and could help healthcare systems save money

Basel, 28 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced a series of five new intended uses for two key cardiac biomarkers using the Elecsys® technology: high sensitive cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide test (NT-proBNP). These gold standard biomarkers³ have proven to be successful in supporting cardiovascular disease management and can help clinicians diagnose heart attacks⁴ (cTnT-hs) and better manage heart failure⁵ (NT-proBNP). Roche's introduction of five new intended uses for these existing, globally accepted diagnostic solutions means more people could benefit from improved cardiovascular diagnostics. By providing greater precision and certainty for clinicians, Roche can help them tackle the world's biggest killer: cardiovascular diseases.

“The five new solutions we launch this month add real value for clinicians by supporting cardiac risk identification and improving diagnosis. In turn, this will help them make early treatment decisions, improve people’s lives and reduce healthcare costs,” said Thomas Schinecker, CEO Roche Diagnostics. “As the market leader in cardiovascular testing Roche is committed to innovation in cardiovascular care and these new intended uses are the first of many solutions planned over the next decade that could help improve the lives of millions of people.”

One of the new intended uses for Elecsys® NT-proBNP supports healthcare professionals in identifying which people with type-2 diabetes (463 million worldwide⁶) are at higher risk of developing cardiovascular disease⁷. Early identification of people at risk means cardioprotective treatment can be started sooner, which could prevent 65% of hospitalisations or deaths⁸. The second newly-launched intended use for NT-proBNP provides healthcare professionals with a biomarker-based solution that identifies people at risk of developing Atrial Fibrillation (AF), an abnormal heart rhythm that can lead to stroke, brain damage and death⁹. More than 37 million people suffer from AF globally¹⁰. NT-proBNP, in combination with a single lead (or higher) electrocardiogram, can help to successfully diagnose AF so therapy can be started to reduce the stroke risk¹¹.

Another important biomarker, Elecsys® cTnT-hs, now provides healthcare professionals with data to help predict heart attack risk and mortality in non-cardiac surgery patients. Every year, over 200 million adults undergo major non-cardiac surgery with 10 million suffering from major adverse cardiac events (MACE) that could be prevented through early and accurate diagnosis¹².

Both Elecsys® NT-proBNP and Elecsys® cTnT-hs can be run on all cobas e® analysers. They are among the first products certified under the new European In Vitro Diagnostics Regulation (IVDR) and available as of today in countries accepting CE mark. Availability in other countries is subject to local registration processes and timelines.

About Elecsys® NT-proBNP
Tests for NT-proBNP, a cardiac hormone that is released into the blood when the heart wall is stretched, are developed and marketed by Roche. NT-proBNP is an objective marker for the aid in diagnosis in individuals suspected of having congestive heart failure and detection of mild forms of cardiac dysfunction. This assay is further indicated for the risk stratification of patients with acute coronary syndrome and congestive heart failure, and it can also be used for monitoring the treatment in patients with left ventricular dysfunction.

Added intended uses for Elecsys® NT-proBNP
(1) Type-2 diabetes and heart failure
463 million people suffer from type-2 diabetes worldwide⁴ and are at higher risk of developing cardiovascular disease. The new intended use of Elecsys® NT-proBNP provides healthcare professionals with a precise biomarker that supports them to identify patients with high cardiovascular risk. This means that effective drug treatment can be started early so that cardioprotective treatment can be optimized. In PONTIAC-I it was shown that 65% of hospitalisations or death could be prevented⁸.

(2) Atrial fibrillation
More than 37 million people suffer from Atrial Fibrillation (AF) and 25% of people over 40 years old develop AF in their lifetime. More than 450 million people aged 70 or above are considered high risk for this disease. Patients with AF are exposed to a fivefold risk of stroke¹³ and therefore brain damage or death¹⁴. One of the key elements in reducing stroke is early detection of people at risk of Atrial Fibrillation by better identification methods. Our second launched intended use for Elecsys® NT-proBNP provides healthcare professionals with a biomarker based solution that identifies people at risk and, in combination with a single lead (or higher) ECG, can aid successful diagnosis so therapy can be started.

About Elecsys® cTnT-hs
The Elecsys cardiac Troponin T high-sensitivity (cTnT-hs) test from Roche, detects cardiac troponin which is the guideline recommended biomarker for the diagnosis of heart attack in clinical practice. In combination with an electrocardiogram (ECG), high-sensitive Troponin has become the gold standard for the diagnosis of heart attack. Using the accelerated ESC 0/1 hour algorithm with the Elecsys cTnT-hs assay, significantly accelerates “rule-in” and “rule-out” decision-making, thereby maximising the potential for effective treatment. At the same time, the faster decision-making may help to better manage the emergency room workload and related costs for healthcare systems¹⁵.

Added intended uses for Elecsys® cTnT-hs in coronary artery disease
(3) Over 200 million adults globally undergo major non-cardiac surgery every year. Of these, over 10 million suffer from major adverse cardiac events (MACE) in the first 30 days after non-cardiac surgery and more than 80% of those are clinically asymptomatic. The new intended use for Elecsys® cTnT-hs provides healthcare professionals with a biomarker that helps to predict the perioperative risk of a heart attack and to a perioperative heart attack in non-cardiac surgeries to allow clinicians to tailor surgery and post-operative care accordingly.

(4) The second newly-launched intended use for Elecsys® cTnT-hs makes the biomarker serve as an aid in assessing the long-term risk of cardiovascular events (death, myocardial infarction, coronary revascularisation, heart failure or ischemic stroke) in asymptomatic individuals.

(5) Elecsys® cTnT-hs is the gold standard for triaging patients suspected of Acute Coronary Syndrome in Emergency Departments and Intensive Care Units The third launched intended use for this biomarker can help to improve early discharge and outpatient management of these patients.

About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References
[1] 17.9 M deaths: https://www.who.int/health-topics/cardiovascular-diseases/#tab=tab_1
[2] A third of all deaths: Mensah, G. A., et al. (2019). "The Global Burden of Cardiovascular Diseases and Risk Factors." 2020 and Beyond 74(20): 2529-2532
[3] Gold standard biomarkers: Ohman EM. Clin Chem 2017; 63: 429
Gold standard biomarkers: McKie, PM., et al. (2016). J Am Coll Cardiol 68(22), 2437-2439
[4] Help clinicians diagnose heart attacks (cTnT-hs): Roff M et al, Eur Heart J 2016; 37: 267
Help clinicians diagnose heart attacks (cTnT-hs): Amsterdam EA et al., Circulation 2014;130:2354
[5] Better manage heart failure (NT-proBNP): Ponikowski P et al., Eur Heart J 2016; 37:2129
Better manage heart failure (NT-proBNP): Yancy CW et al, Circulation. 2017;136:e137;
[6] 463 million diabetics worldwide: Saeedi P et al., Diabetes Res Clin Pract 2019
[7] “NT-proBNP supports healthcare professionals in identifying which type-2 diabetes patients are at a higher risk of developing cardiovascular disease”: Huelsmann M. et al. JACC. 2013, 62:1365-72
[8] PONTIAC reference: 65% of hospitalisations or death: Huelsmann, M. et al., J Am Coll Cardiol., 2013; Vol. 62, pp. 1365-1372 [same as ref 9]
[9] Atrial Fibrillation (AF), the most common of abnormal heart rhythms which can lead to stroke, brain damage and death (ref: Hindricks, G. Eur Heart J (2020) Aug 29;ehaa612
Atrial Fibrillation (AF), the most common of abnormal heart rhythms which can lead to stroke, brain damage and death (ref: January C.T., et al. Circulation (2014); 130:e199–e267)
Atrial Fibrillation (AF), the most common of abnormal heart rhythms which can lead to stroke, brain damage and death(ref: January, C.T. Circulation (2019); 140(2):e125-e151)
[10] More than 37 million people suffer from AF globally (ref: Lippi G. et al (2020), International Journal of Stroke. 16 (2): 217-221)
[11 NT-proBNP, in combination with a single lead (or higher) electrocardiogram, can help to successfully diagnose AF so therapy can be started.(ref: Gudmundsdottir, K. et al. (2020). Eurospace 22, 24-32)
[12] Every year, over 200 million adults undergo major non-cardiac surgery⁶ with 10 million suffering from major adverse cardiac events (MACE) that could be prevented through early and accurate diagnosis. (ref: Devereaux PJ, Sessler DI. (2015). Cardiac complications in patients undergoing major noncardiac surgery. N Engl J Med 373, 2258-2269)
[13] Patients with AF are exposed to a fivefold risk of stroke → Patients with AF have a 5-fold increased risk of stroke. (ref: Wolf et al, Stroke Vol 22, No 8 August 1991)
[14] and therefore brain damage or death → and greater frequency of brain damage, disability or death. (ref: Alkhouli, M. JACC Clin     Electrophysiol (2018); 4(5):618-625.
and therefore brain damage or death → and greater frequency of brain damage, disability or death. (ref:Marini, C. Stroke (2005); 36(6):1115-1119.
and therefore brain damage or death → and greater frequency of brain damage, disability or death. (ref:Hannon, N. Cerebrovasc Dis (2010); 29(1):43-49.
[15] Using the accelerated ESC 0/1 hour algorithm with the Elecsys cTnT-hs assay, significantly accelerates “rule-in” and “rule-out” decision-making, thereby maximising the potential for effective treatment. At the same time, the faster decision-making may help to better manage the emergency room workload and related costs for healthcare systems. (ref: Kiril M Stoyanov et al. (2020) Acute Cardiovascular Care, 9(1): 39–51,

Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Dr. Nicolas Dunant
Phone: +41 61 687 05 17
Patrick Barth
Phone: +41 61 688 44 86
Dr. Daniel Grotzky
Phone: +41 61 688 31 10
Karsten Kleine
Phone: +41 61 682 28 31
Nina Mählitz
Phone: +41 79 327 54 74
Nathalie Meetz
Phone: +41 61 687 43 05
Dr. Barbara von Schnurbein
Phone: +41 61 687 89 67


Roche Investor Relations
Dr. Karl Mahler
Phone: +41 61 68-78503
e-mail: karl.mahler@roche.com
Jon Kaspar Bayard
Phone: +41 61 68-83894
e-mail: jon_kaspar.bayard@roche.com
Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com
Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com
Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com
Dr. Gerard Tobin
Phone: +41 61 68-72942
e-mail: gerard.tobin@roche.com
Investor Relations North America
Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com
Dr. Lisa Tuomi
Phone: +1 650 467 8737
e-mail: tuomi.lisa@gene.com

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Mandalay Resources Corporation tillkännager resultatrapporten för första kvartalet 202115.5.2021 14:02:50 CEST | Pressemelding

TORONTO, May 15, 2021 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation (”Mandalay” eller ”bolaget”) (TSX: MND, OTCQB: MNDJF) tillkännager resultatrapporten för kvartalet som slutade den 31 mars 2021. Bolagets sammanfattade och konsoliderade delårsrapporter för kvartalet som slutade den 31 mars 2021, tillsammans med ledningens diskussion och analys (”MD&A”) för samma period, finns tillgängliga under bolagets profil på www.sedar.com och på bolagets webbplats www.mandalayresources.com. Alla valutor i detta pressmeddelande avser US-dollar om inget annat anges. Höjdpunkter för första kvartalet 2021: Kvartalsintäkter på 52,6 miljoner USD, de högsta sedan andra kvartalet 2016;Justerad EBITDA på 26,1 miljoner USD, det tredje högsta i bolagets historia;Justerat nettoresultat på 5,6 miljoner USD (0,06 USD eller 0,08 CAD per aktie); ochKonsoliderat nettoresultat på 25,5 miljoner USD (0,28 USD eller 0,35 CAD per aktie). Dominic Duffy, styrelseordförande och CEO på Mandalay, kommenterar: ”Mandala

Antal aktier i Nexstim Abp efter första momentet i processen för att minska antalet aktier14.5.2021 20:00:00 CEST | Pressemelding

Företagsmeddelande,Helsingfors, 14.5.2021 kl. 21.00 (EEST) Antal aktier i Nexstim Abp efter första momentet i processen för att minska antalet aktier Bolagsstämman av Nexstim Abp (NXTMH:HEX, NXTMS:STO) (”Nexstim” eller ”bolaget”) fattade 11 maj 2021 beslut om att minska antalet aktier i bolaget utan att minska aktiekapitalet genom att vederlagsfritt ge ut nya aktier till aktieägarna, och genom att vederlagsfritt lösa in bolagets egna aktier så att hundra (100) nuvarande aktier i bolaget ska motsvara en (1) aktie efter att arrangemangen för att minska antalet aktier i bolaget har genomförts. Som en del av arrangemangen med avseende på de aktieägare som på transaktionsdagen (enligt definitionen nedan) är registrerade i Nexstims aktieägarförteckning hos Euroclear Finland Ab fattade bolagsstämman beslut om att bolaget ska 14 maj 2021 (”transaktionsdagen”) vederlagsfritt emittera högst 1 000 000 nya aktier så att antalet aktier per värdeandelskonto som ägs av dessa aktieägare är delbart med

Quantity of shares in Nexstim Plc after completion of the first phase in reducing the quantity of shares14.5.2021 20:00:00 CEST | Press release

Company announcement,Helsinki, 14 May 2021 at 9 PM (EEST) Quantity of shares in Nexstim Plc after completion of the first phase in reducing the quantity of shares Annual General Meeting of Nexstim Plc (NXTMH:HEX, NXTMS:STO) (“Nexstim” or “Company”) resolved on 11 May 2021 to reduce the quantity of Nexstim's shares without reducing share capital by way of issuing new shares to its shareholders without consideration, and by redemption of Company's own shares without consideration, in such a way that each current 100 shares of the Company shall correspond to one share of the Company after the arrangements related to the reduction of the quantity of Company's shares are completed. As a part of the arrangements in respect of shareholders registered on the Transaction Day (as defined below) in the shareholders’ register of Nexstim held by Euroclear Finland Ltd, the Annual General Meeting resolved that the Company shall issue on 14 May 2021 (the "Transaction Day") a maximum of 1,000,000 new s

IMCD Colombia expands into new markets through the acquisition of Siliconas y Químicos14.5.2021 20:00:00 CEST | Press release

ROTTERDAM, The Netherlands (14 May 2021) – IMCD N.V. (“IMCD” or “Company”), a leading distributor of speciality chemicals and ingredients, today announces that IMCD Colombia acquired the Colombian speciality distributor, Siliconas y Químicos S.A.S. (“Siliconas y Químicos”). “We are delighted to further expand our presence in Latin America with the acquisition of Siliconas y Químicos,” said Marcus Jordan, Americas President, IMCD. “The company’s strategy of being ‘Specialists in Specialities’ closely aligns with IMCD and its expertise in personal care, coatings, silicones, and other speciality industrial markets perfectly complements our existing pharmaceuticals, food and nutrition business in Colombia.” Based in Bogotá, Siliconas y Químicos has experienced steady growth since its inception in 2000, generated a revenue of USD 9 million in 2020, and adds 25 employees to the IMCD Colombia team. Siliconas y Químicos is ISO 9001:2015 certified and operates across Colombia with strategic out

Touax: Q1 2021 restated revenues from activities14.5.2021 17:45:00 CEST | Press release

PRESS RELEASE Paris, 14 May 2021 – 5.45 p.m. YOUR OPERATIONAL LEASING SOLUTION FOR SUSTAINABLE TRANSPORTATION Q1 2021 restated revenues from activities Restated revenues from activities amounted to €24.6m in Q1 2021, stable in constant dollars compared to the same period in 2020.Favourable outlook with a significant order book New segmentation of revenues betweenownedactivities and management activities. In order to enable a more detailed and more accurate reading of its activities, the Group decided to update the key indicators of its quarterly report: Revenues from activities are restated in order to present ownedactivities separately from management activities. For management activities, leasing revenue from investor-owned equipment is replaced by management fees, which correspond to the net contribution of the leasing management activity to the Group's performance. This presentation showssyndication fees, sales feesand now management fees, grouped together under management activity

CONDITIONS FOR THE RIKSBANK´S PURCHASES OF COMMERCIAL PAPER14.5.2021 16:20:00 CEST | Press release

Bid procedure, 2021-05-19CertificateCommercial paper issued in SEK by non-financial companies with their registered office in Sweden and with a remaining maturity of up to six months on the Bid date. i.e. with the latest maturity date as of 2021-11-19 Delivery may not be made in commercial paper purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Special terms, i.e. the purchase may not have been made after 2021-05-07 BidsCounterparties may make one bid per Credit rating class and maturity class. Bids are made to tel 08-696 69 70 and confirmed by e-mail to EOL@riksbank.se.Bid date2021-05-19Bid times09.00-09.30 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)SEK 4 billionHighest permitted bid volume (corresponding nominal amount)The total bid volume from one Counterparty for the two Credit rating classes may not exceed SEK 4 billion. No bid may contain Commercial paper in excess of SEK 250 million issued by the s

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS14.5.2021 16:20:00 CEST | Press release

Bid procedure, 2021-05-21BondsSWEDISH GOVERNMENT: 1053. SE0002829192. 2039-03-30 SWEDISH GOVERNMENT: 1063, SE0015193313, 2045-11-24 Bid date2021-05-21Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)1053: 750 mln SEK +/-350 mln SEK 1063: 500 mln SEK +/-250 mln SEK Highest permitted bid volume (corresponding nominal amount)1053: 750 mln SEK per bid 1063: 500 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 10.15 (CET/CEST) on the Bid dateDelivery and payment date2021-05-25Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2021-05-14 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions c